協和キリンの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2017/01/20 | 1,580 | 1,603 | 1,571 | 1,593 | +11 | +0.7% | 922,300 |
| 2017/01/19 | 1,572 | 1,592 | 1,569 | 1,582 | +15 | +1% | 768,200 |
| 2017/01/18 | 1,574 | 1,575 | 1,555 | 1,567 | -6 | -0.4% | 801,600 |
| 2017/01/17 | 1,609 | 1,615 | 1,571 | 1,573 | -32 | -2% | 774,600 |
| 2017/01/16 | 1,629 | 1,629 | 1,595 | 1,605 | -25 | -1.5% | 896,600 |
| 2017/01/13 | 1,617 | 1,633 | 1,614 | 1,630 | +32 | +2% | 1,323,700 |
| 2017/01/12 | 1,621 | 1,627 | 1,592 | 1,598 | -57 | -3.4% | 1,180,200 |
| 2017/01/11 | 1,644 | 1,657 | 1,624 | 1,655 | +18 | +1.1% | 885,300 |
| 2017/01/10 | 1,675 | 1,684 | 1,634 | 1,637 | -35 | -2.1% | 1,555,300 |
| 2017/01/06 | 1,668 | 1,681 | 1,659 | 1,672 | +27 | +1.6% | 1,022,900 |
| 2017/01/05 | 1,638 | 1,653 | 1,635 | 1,645 | +6 | +0.4% | 838,400 |
| 2017/01/04 | 1,635 | 1,647 | 1,632 | 1,639 | +23 | +1.4% | 903,600 |
| 2016/12/30 | 1,599 | 1,625 | 1,598 | 1,616 | +11 | +0.7% | 685,800 |
| 2016/12/29 | 1,612 | 1,626 | 1,600 | 1,605 | -11 | -0.7% | 562,900 |
| 2016/12/28 | 1,627 | 1,627 | 1,607 | 1,616 | -22 | -1.3% | 575,900 |
| 2016/12/27 | 1,634 | 1,649 | 1,632 | 1,638 | +6 | +0.4% | 694,200 |
| 2016/12/26 | 1,606 | 1,639 | 1,598 | 1,632 | +45 | +2.8% | 935,400 |
| 2016/12/22 | 1,616 | 1,618 | 1,578 | 1,587 | -36 | -2.2% | 917,200 |
| 2016/12/21 | 1,640 | 1,640 | 1,616 | 1,623 | -9 | -0.6% | 952,900 |
| 2016/12/20 | 1,629 | 1,635 | 1,617 | 1,632 | +5 | +0.3% | 805,200 |
| 2016/12/19 | 1,608 | 1,632 | 1,605 | 1,627 | +20 | +1.2% | 797,500 |
| 2016/12/16 | 1,595 | 1,607 | 1,590 | 1,607 | +14 | +0.9% | 1,164,300 |
| 2016/12/15 | 1,606 | 1,608 | 1,578 | 1,593 | -7 | -0.4% | 1,205,400 |
| 2016/12/14 | 1,628 | 1,634 | 1,595 | 1,600 | -36 | -2.2% | 1,194,100 |
| 2016/12/13 | 1,578 | 1,637 | 1,572 | 1,636 | +66 | +4.2% | 1,415,000 |
| 2016/12/12 | 1,579 | 1,585 | 1,554 | 1,570 | +15 | +1% | 1,633,300 |
| 2016/12/09 | 1,516 | 1,562 | 1,516 | 1,555 | +36 | +2.4% | 2,725,700 |
| 2016/12/08 | 1,529 | 1,534 | 1,512 | 1,519 | -16 | -1% | 1,772,100 |
| 2016/12/07 | 1,569 | 1,569 | 1,529 | 1,535 | -40 | -2.5% | 1,740,500 |
| 2016/12/06 | 1,608 | 1,608 | 1,570 | 1,575 | -19 | -1.2% | 1,395,300 |
| 2016/12/05 | 1,607 | 1,624 | 1,587 | 1,594 | -21 | -1.3% | 1,038,600 |
| 2016/12/02 | 1,613 | 1,618 | 1,602 | 1,615 | -12 | -0.7% | 969,900 |
| 2016/12/01 | 1,645 | 1,658 | 1,618 | 1,627 | -5 | -0.3% | 1,209,300 |
| 2016/11/30 | 1,672 | 1,673 | 1,625 | 1,632 | -37 | -2.2% | 1,691,600 |
| 2016/11/29 | 1,681 | 1,683 | 1,657 | 1,669 | -8 | -0.5% | 1,472,900 |
| 2016/11/28 | 1,688 | 1,695 | 1,665 | 1,677 | -11 | -0.7% | 813,400 |
| 2016/11/25 | 1,685 | 1,697 | 1,677 | 1,688 | +12 | +0.7% | 959,900 |
| 2016/11/24 | 1,707 | 1,707 | 1,676 | 1,676 | -40 | -2.3% | 1,113,200 |
| 2016/11/22 | 1,690 | 1,722 | 1,687 | 1,716 | +17 | +1% | 1,279,900 |
| 2016/11/21 | 1,700 | 1,713 | 1,692 | 1,699 | +35 | +2.1% | 1,228,600 |
| 2016/11/18 | 1,691 | 1,694 | 1,658 | 1,664 | -18 | -1.1% | 1,492,100 |
| 2016/11/17 | 1,675 | 1,693 | 1,664 | 1,682 | +4 | +0.2% | 1,013,300 |
| 2016/11/16 | 1,658 | 1,685 | 1,647 | 1,678 | +27 | +1.6% | 1,576,500 |
| 2016/11/15 | 1,678 | 1,678 | 1,641 | 1,651 | -27 | -1.6% | 1,660,900 |
| 2016/11/14 | 1,700 | 1,720 | 1,663 | 1,678 | -13 | -0.8% | 1,658,600 |
| 2016/11/11 | 1,706 | 1,714 | 1,654 | 1,691 | +105 | +6.6% | 3,739,500 |
| 2016/11/10 | 1,545 | 1,591 | 1,517 | 1,586 | +155 | +10.8% | 2,223,300 |
| 2016/11/09 | 1,514 | 1,533 | 1,424 | 1,431 | -70 | -4.7% | 2,079,000 |
| 2016/11/08 | 1,510 | 1,567 | 1,489 | 1,501 | -6 | -0.4% | 1,040,000 |
| 2016/11/07 | 1,519 | 1,524 | 1,500 | 1,507 | +2 | +0.1% | 1,241,300 |
2101～
2150
件表示中 / 3768件
類似銘柄と比較する
現在ご覧いただいている「協和キリン」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 協和キリン | 263,900円 | -3.5% | -11.3% | 2.27% | 24.24倍 | 1.64倍 |
|
キリン傘下。医薬品、バイオが主力。独自の抗体高活性化技術に強み。富士フイルムと提携 |
| アステラス薬 | 169,200円 | +0.9% | +380.2% | 4.61% | 23.31倍 | 2.00倍 |
|
医薬品国内２位。開発技術起点の研究開発体制。前立腺がん薬が柱。遺伝子・細胞治療技術育成 |
| 塩野義 | 258,000円 | +20.9% | +10.6% | 2.56% | 12.20倍 | 1.61倍 |
|
抗ＨＩＶ薬が大型製品に。感染症、疼痛・中枢神経領域に強み。米国に積極展開。欧州、アジア開拓 |
| エーザイ | 467,600円 | +0.1% | -3.4% | 3.42% | 31.79倍 | 1.57倍 |
|
神経系、がん領域に強み。認知症薬は米バイオジェンと、抗がん薬では米メルクと国際協業推進 |
| 小野薬 | 166,100円 | +0.6% | +43.3% | 4.82% | 11.65倍 | 1.00倍 |
|
医療用医薬品専業の中堅。自社開発品多い。先駆的がん免疫阻害剤「オプジーボ」が成長牽引 |
市場注目の銘柄
チャート関連のコラム
